Johan Kuiper
Professor
Therapeutic immunomodulation
Leiden University
Netherlands
Biography
Dr. Kuiper has studied biology, specializing in biochemistry and immunology at the University of Groningen. After graduation in 1984, he obtained his PhD from Leiden University in 1989. In 2007, he became Director of Education of the LACDR, and in November 2008 he became Professor of Therapeutic Immunomodulation at Leiden University. His present research is mainly focused at on immunomodulation of inflammatory responses that lead to the development of atherosclerotic plaques. The regulation of pro-inflammatory cytokines by various strategies such as tolerance induction, [DNA] vaccination and modulation of the activity of natural killer T cells is his main topic of research. In addition, dendritic cell therapy is exploited as a new therapy for atherosclerosis. Dr. Kuiper is an Established Investigator of the Netherlands Heart Foundation.
Research Interest
Therapeutic immunomodulation.
Publications
-
Ellenbroek G., Puijvelde G.H.M. van, Anas A.A., Bot M., Asbach M., Schoneveld A., van Santbrink P.J., Foks A.C., Timmers L., Doevendans P.A., Pasterkamp G., Hoefer I.E., Poll T. van der, Kuiper J. & Jager S.C.A. de (2017), Leukocyte TLR5 deficiency inhibits atherosclerosis by reduced macrophage recruitment and defective T-cell responsiveness, SCIENTIFIC REPORTS 2017(7): 42688.
-
Bot I. & Kuiper J. (2017), Stressed brain, stressed heart?, 389(10071): 770-771.
-
Bot I., Ortiz Zacarias N.V., Witte W.E. de, Vries H. de, Santbrink P.J. van, Velden D. van der, Kroener M.J., Berg D.J. van den, Stamos D., Lange E.C.M. de, Kuiper J., IJzerman A.P. & Heitman L.H. (2017), A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy, Scientific Reports 2017(7): 52.
